Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
LAB Standard BioTools Inc
- Stocks
- Healthcare
- NASDAQ: LAB
Price (delayed)
$1.07
Market cap
$406.41M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.34
Enterprise value
$287.06M
Fluidigm focuses on the most pressing needs in translational and clinical research, including cancer, immunology, and immunotherapy. Using proprietary CyTOF® and microfluidics technologies, it develops, manufactures, and markets multi-omic solutions
Highlights
Standard BioTools's EPS has soared by 66% YoY and by 35% from the previous quarter
The debt has dropped by 66% year-on-year and by 4.4% since the previous quarter
The company's net income fell by 48% YoY but it rose by 4.4% QoQ
Standard BioTools's revenue has increased by 34% YoY but it has decreased by 2.7% from the previous quarter
Standard BioTools's equity has decreased by 21% YoY and by 3.6% QoQ
LAB's gross margin is down by 4.3% YoY and by 2.7% from the previous quarter
Key stats
What are the main financial stats of LAB
Market
Valuations
Earnings
Shares outstanding
379.82M
Market cap
$406.41M
Enterprise value
$287.06M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.89
Price to sales (P/S)
2.39
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.69
Revenue
$169.69M
Gross profit
$79.82M
Operating income
-$148.02M
Net income
-$132.76M
EBIT
-$129.15M
EBITDA
-$107.55M
Free cash flow
-$123.89M
Per share
Balance sheet
Liquidity
EPS
-$0.34
EPS diluted
-$0.34
Free cash flow per share
-$0.33
Book value per share
$1.2
Revenue per share
$0.45
TBVPS
$1.16
Total assets
$579.6M
Total liabilities
$125M
Debt
$31.53M
Equity
$454.6M
Working capital
$287.78M
Debt to equity
0.07
Current ratio
6.12
Quick ratio
5.22
Net debt/EBITDA
1.11
Margins
Efficiency
Dividend
EBITDA margin
-63.4%
Gross margin
47%
Net margin
-78.2%
Operating margin
-87.2%
Return on assets
-20.6%
Return on equity
-27.6%
Return on invested capital
-46%
Return on capital employed
-24.7%
Return on sales
-76.1%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
LAB stock price
How has the Standard BioTools stock price performed over time
Intraday
-4.04%
1 week
-10.83%
1 month
-7.76%
1 year
-55.6%
YTD
-38.86%
QTD
-0.93%
Financial performance
How have Standard BioTools's revenue and profit performed over time
Revenue
$169.69M
Gross profit
$79.82M
Operating income
-$148.02M
Net income
-$132.76M
Gross margin
47%
Net margin
-78.2%
The company's net income fell by 48% YoY but it rose by 4.4% QoQ
Standard BioTools's revenue has increased by 34% YoY but it has decreased by 2.7% from the previous quarter
Standard BioTools's gross profit has increased by 28% YoY but it has decreased by 5% from the previous quarter
LAB's operating income is down by 23% YoY but it is up by 16% from the previous quarter
Price vs fundamentals
How does LAB's price correlate with its fundamentals
Growth
What is Standard BioTools's growth rate over time
Valuation
What is Standard BioTools stock price valuation
P/E
N/A
P/B
0.89
P/S
2.39
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.69
Standard BioTools's EPS has soared by 66% YoY and by 35% from the previous quarter
The price to book (P/B) is 32% lower than the last 4 quarters average of 1.3
Standard BioTools's equity has decreased by 21% YoY and by 3.6% QoQ
The P/S is 37% below the last 4 quarters average of 3.8 and 11% below the 5-year quarterly average of 2.7
Standard BioTools's revenue has increased by 34% YoY but it has decreased by 2.7% from the previous quarter
Efficiency
How efficient is Standard BioTools business performance
The ROE has soared by 91% YoY and by 24% QoQ
The company's return on assets rose by 32% YoY and by 23% QoQ
Standard BioTools's ROS has decreased by 15% YoY
The return on invested capital has declined by 14% year-on-year
Dividends
What is LAB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for LAB.
Financial health
How did Standard BioTools financials performed over time
LAB's total liabilities is down by 38% year-on-year and by 11% since the previous quarter
The current ratio is up by 36% YoY and by 7% from the previous quarter
The debt is 93% smaller than the equity
The debt has dropped by 66% year-on-year and by 4.4% since the previous quarter
LAB's debt to equity has dropped by 56% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.